ArticleSaudi medical journal2026
Plasma VGF as a Predictive Biomarker for Early Acute Kidney Injury in Critically Ill Elderly Patients:
Article in Saudi medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess whether VGF nerve growth factor inducible (VGF) can serve as a reliable predictor of acute kidney injury (AKI) among patients requiring intensive care. Methods: We first conducted a Mendelian randomization (MR) analysis to explore the potential causal link between plasma VGF levels and AKI risk. Subsequently, 128 critically ill individuals admitted to our intensive care unit were prospectively enrolled. Within 24 hours of either hospital admission or clinical decline, both blood and urine specimens were obtained. We measured VGF concentrations in plasma and urine, along with plasma cystatin C (pCysC), plasma and urinary neutrophil gelatinase-associated lipocalin (NGAL), and urinary N-acetyl-β-D-glucosaminidase (NAG). Kidney function was assessed using serum creatinine and hourly urine output. Receiver operating characteristic (ROC) curve analysis was employed to evaluate each biomarker 's predictive capacity for AKI. Results: The inverse-variance weighted (IVW) method revealed a statistically significant positive association between plasma VGF levels and AKI development. The area under the ROC curve (AUC) values for individual markers were as follows: pVGF (0.651), uVGF (0.483), pCysC (0.750), pNGAL (0.804), uNGAL (0.803), and uNAG (0.632). When pVGF, pCysC, and pNGAL were combined, the AUC increased to 0.861, indicating substantially better predictive performance than any single biomarker. Conclusions: Plasma VGF shows promise as a predictive biomarker for AKI in critically ill populations. Its diagnostic utility is considerably strengthened when measured alongside pCysC and pNGAL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.